FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896945405> ?p ?o ?g. }

• W2896945405 endingPage "2009" @default.
• W2896945405 startingPage "2002" @default.
• W2896945405 abstract "Does pre-treatment with a low dose of mifepristone improve irregular vaginal bleeding patterns during the initial 3 months after LNG-IUS placement? Mifepristone treatment prior to LNG-IUS insertion results in significantly lower bleeding and spotting rates but no significant reduction at 3 months post insertion. One of the leading causes of premature discontinuation of the LNG-IUS is unscheduled bleeding in the first months following its insertion. Up to now, there has been no effective treatment to prevent this side effect which reduces continuation rates for one of the most effective contraceptives. This randomized, double blinded, controlled trial was conducted between 2009 and 2015. In total, 68 women opting for a LNG-IUS were screened for eligibility, of whom 58 were randomized at a ratio of 1:1 in blocks of 10 to pre-treatment with mifepristone or a comparator. The main outcome was the rate of bleeding and spotting days reported during the first 3 months post LNG-IUS 52 mg placement. Healthy women with regular and normal menstrual cycles aged 18–43 years were enrolled at a single center in a university hospital; 29 were allocated to 2 months pre-treatment with a low dose mifepristone and 29 to the comparator prior to insertion of the LNG-IUS. Women were advised to use barrier methods during the pre-treatment period. Bleeding diaries were collected for the pre-treatment period and for the first 6 months after the LNG-IUS placement. There were no differences in demographic or baseline characteristics between the study groups. Data for analysis of the main outcome were contributed by a per protocol population of 19 women per group. There was a significant lower bleeding and spotting rate in the mifepristone group (−17.8% points, P < 0.001) after 2 months of pre-treatment but after the LNG-IUS insertion no significant difference could be seen. While no pregnancies occurred prior to LNG-IUS insertion in the mifepristone group, there were three unintended pregnancies in the comparator group which emphasizes the need for a reliable contraceptive potential in any pre-treatment regimen used in clinical practice. The use of mifepristone prior to the LNG-IUS insertion in this trial was used as prophylaxis against unscheduled bleeding after the placement of the device. Although this side effect constitutes a major concern in a clinical setting, only a subset of women are at risk. This is the first study using pre-treatment to attempt improved bleeding control. The differences were small and the effect was short lasting but the reduced rate of bleeding and spotting observed during the first month following LNG-IUS insertion, even though not statistically significant, indicates that this approach may be further explored. The fact that there were three pregnancies in the comparator group stresses the need for any pre-treatment to also protect against unplanned pregnancy. Modified treatment protocols of mifepristone could be used prior to the LNG-IUS insertion to investigate possible further improvement of the outcome. The effect size of the current dose used might have been more prominent in women with LNG-IUS if the treatment also continued some weeks after the placement of the device. Although the low dose of mifepristone used in this trial is not available in Europe, other progesterone receptor modulators currently available could be investigated in larger clinical trials. To avoid unintended pregnancy in the pretreatment period, the dosage used should, ideally, also be effective for contraception and the pretreatment period should be kept as short as possible. This study was funded by the Swedish Research Council (2012-2844, 2017-00932), Stockholm County Council and Karolinska Institutet (ALF). Conflicts of interests for K.G.D. and H.K.K. are listed at the end of the paper. The other authors have no conflicts of interest. EudraCT number 2009-009014-40. Regional ethical review board at Karolinska Institutet permit 2009/144-31/4. 20 July 2009. 24 November 2009." @default.
• W2896945405 created "2018-10-26" @default.
• W2896945405 creator A5002928798 @default.
• W2896945405 creator A5021933390 @default.
• W2896945405 creator A5048848152 @default.
• W2896945405 creator A5062204446 @default.
• W2896945405 date "2018-10-08" @default.
• W2896945405 modified "2023-10-10" @default.
• W2896945405 title "Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control – a randomized controlled trial" @default.
• W2896945405 cites W1964336207 @default.
• W2896945405 cites W1971291813 @default.
• W2896945405 cites W1974707749 @default.
• W2896945405 cites W1990706232 @default.
• W2896945405 cites W2002100432 @default.
• W2896945405 cites W2016200212 @default.
• W2896945405 cites W2038587859 @default.
• W2896945405 cites W2045524208 @default.
• W2896945405 cites W2047372977 @default.
• W2896945405 cites W2047877984 @default.
• W2896945405 cites W2048097238 @default.
• W2896945405 cites W2057430669 @default.
• W2896945405 cites W2059089274 @default.
• W2896945405 cites W2065138496 @default.
• W2896945405 cites W2066564642 @default.
• W2896945405 cites W2102395114 @default.
• W2896945405 cites W2106587450 @default.
• W2896945405 cites W2111008791 @default.
• W2896945405 cites W2124714566 @default.
• W2896945405 cites W2127085373 @default.
• W2896945405 cites W2155493571 @default.
• W2896945405 cites W2162160149 @default.
• W2896945405 cites W2166028293 @default.
• W2896945405 cites W2171626715 @default.
• W2896945405 cites W2586561409 @default.
• W2896945405 doi "https://doi.org/10.1093/humrep/dey296" @default.
• W2896945405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31184694" @default.
• W2896945405 hasPublicationYear "2018" @default.
• W2896945405 type Work @default.
• W2896945405 sameAs 2896945405 @default.
• W2896945405 citedByCount "13" @default.
• W2896945405 countsByYear W28969454052019 @default.
• W2896945405 countsByYear W28969454052020 @default.
• W2896945405 countsByYear W28969454052022 @default.
• W2896945405 countsByYear W28969454052023 @default.
• W2896945405 crossrefType "journal-article" @default.
• W2896945405 hasAuthorship W2896945405A5002928798 @default.
• W2896945405 hasAuthorship W2896945405A5021933390 @default.
• W2896945405 hasAuthorship W2896945405A5048848152 @default.
• W2896945405 hasAuthorship W2896945405A5062204446 @default.
• W2896945405 hasBestOaLocation W28969454051 @default.
• W2896945405 hasConcept C131872663 @default.
• W2896945405 hasConcept C141071460 @default.
• W2896945405 hasConcept C168563851 @default.
• W2896945405 hasConcept C2778715236 @default.
• W2896945405 hasConcept C2778826759 @default.
• W2896945405 hasConcept C2779076696 @default.
• W2896945405 hasConcept C2779234561 @default.
• W2896945405 hasConcept C2780186607 @default.
• W2896945405 hasConcept C2908647359 @default.
• W2896945405 hasConcept C2986817661 @default.
• W2896945405 hasConcept C54355233 @default.
• W2896945405 hasConcept C71924100 @default.
• W2896945405 hasConcept C86803240 @default.
• W2896945405 hasConcept C99454951 @default.
• W2896945405 hasConceptScore W2896945405C131872663 @default.
• W2896945405 hasConceptScore W2896945405C141071460 @default.
• W2896945405 hasConceptScore W2896945405C168563851 @default.
• W2896945405 hasConceptScore W2896945405C2778715236 @default.
• W2896945405 hasConceptScore W2896945405C2778826759 @default.
• W2896945405 hasConceptScore W2896945405C2779076696 @default.
• W2896945405 hasConceptScore W2896945405C2779234561 @default.
• W2896945405 hasConceptScore W2896945405C2780186607 @default.
• W2896945405 hasConceptScore W2896945405C2908647359 @default.
• W2896945405 hasConceptScore W2896945405C2986817661 @default.
• W2896945405 hasConceptScore W2896945405C54355233 @default.
• W2896945405 hasConceptScore W2896945405C71924100 @default.
• W2896945405 hasConceptScore W2896945405C86803240 @default.
• W2896945405 hasConceptScore W2896945405C99454951 @default.
• W2896945405 hasFunder F4320322315 @default.
• W2896945405 hasFunder F4320322581 @default.
• W2896945405 hasIssue "11" @default.
• W2896945405 hasLocation W28969454051 @default.
• W2896945405 hasLocation W28969454052 @default.
• W2896945405 hasOpenAccess W2896945405 @default.
• W2896945405 hasPrimaryLocation W28969454051 @default.
• W2896945405 hasRelatedWork W1663154176 @default.
• W2896945405 hasRelatedWork W2008016108 @default.
• W2896945405 hasRelatedWork W2123565902 @default.
• W2896945405 hasRelatedWork W2126289694 @default.
• W2896945405 hasRelatedWork W2158108564 @default.
• W2896945405 hasRelatedWork W2380581393 @default.
• W2896945405 hasRelatedWork W2900342039 @default.
• W2896945405 hasRelatedWork W1443608016 @default.
• W2896945405 hasRelatedWork W2529554939 @default.
• W2896945405 hasRelatedWork W2739355079 @default.
• W2896945405 hasVolume "33" @default.
• W2896945405 isParatext "false" @default.
• W2896945405 isRetracted "false" @default.

• next